Nevirapine pharmacokinetics in HIV-infected and HIV/HCV-coinfected individuals.
OBJECTIVE
An increased risk of drug-related liver injury has been repeatedly reported in individuals infected with hepatitis C virus (HCV) receiving the antiretroviral drug nevirapine. This study was undertaken to assess the differences in the pharmacokinetics of nevirapine between patients with HIV/HCV coinfection and HIV infection that could explain higher rates of hepatotoxicity.


METHODS
A 12 h pharmacokinetic analysis was performed in 18 patients: 7 HIV/HCV-coinfected and 11 HIV-monoinfected. Advanced liver disease was an exclusion criterion in order to assess the impact of chronic HCV infection alone.


RESULTS
Comparing the two groups, no difference was observed between minimum and maximum drug levels or total drug exposure in terms of area under the curve.


CONCLUSIONS
Hepatitis C coinfection does not alter the pharmacokinetics of nevirapine in patients with preserved liver function.
Vogel
Martin
M
Department of Internal Medicine I, Bonn University, Germany.
Bertram
Norbert
N
Wasmuth
Jan-Christian
JC
Wyen
Christoph
C
Voigt
Esther
E
Schwarze-Zander
Carolynne
C
Sudhop
Thomas
T
Fätkenheuer
Gerd
G
Rockstroh
Jürgen K
JK
Reichel
Christoph
C
D000328:Adult; D000998:Antiviral Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D019829:Nevirapine / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D044967:Serum / Q000737:chemistry
D000998:Antiviral Agents; D019829:Nevirapine